Yi Xing1, Yi Tang1, Lina Zhao1, Qi Wang1, Wei Qin1, Xiaojuan Ji2, Jinlan Zhang3, Jianping Jia4. 1. Department of Neurology, Xuan Wu Hospital, Capital Medical University, Beijing, China. 2. Department of Cadre Health Care, Beijing Jishuitan Hospital, Beijing, China. 3. State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China. Electronic address: zhjl@imm.ac.cn. 4. Department of Neurology, Xuan Wu Hospital, Capital Medical University, Beijing, China; Department of Neurology, Beijing Friendship Hospital, Capital Medical University, Beijing, China. Electronic address: jiajp@vip.126.com.
Abstract
BACKGROUND: The abnormal metabolism of ceramides may account for the pathogenesis of Parkinson's disease dementia (PDD). However, the effect of ceramides on cognitive domain impairments and neuropsychiatric symptoms of PDD remains unknown. METHODS: A total of 38 PDD, 40 PD with no cognitive impairment (PD-NC) and 40 normal controls were included. A series of cognitive tests and the Neuropsychiatric Inventory (NPI) were used to assess cognitive domains and neuropsychiatric symptoms. A non-fasting blood sample was obtained from each subject. Plasma ceramide levels were tested by HPLC-MS/MS analysis. RESULTS: C14:0 and C24:1 levels were significantly higher in PDD than in PD-NC and normal controls. Verbal memory was negatively correlated with C14:0 and C24:1. After controlling for confounding factors, C22:0, C20:0 and C18:0 were significantly associated with hallucinations, anxiety and sleep behavior disturbances, respectively. CONCLUSION: In PDD, the increase in ceramide levels was correlated with decreased memory function and associated with higher odds of multiple neuropsychiatric symptoms.
BACKGROUND: The abnormal metabolism of ceramides may account for the pathogenesis of Parkinson's disease dementia (PDD). However, the effect of ceramides on cognitive domain impairments and neuropsychiatric symptoms of PDD remains unknown. METHODS: A total of 38 PDD, 40 PD with no cognitive impairment (PD-NC) and 40 normal controls were included. A series of cognitive tests and the Neuropsychiatric Inventory (NPI) were used to assess cognitive domains and neuropsychiatric symptoms. A non-fasting blood sample was obtained from each subject. Plasma ceramide levels were tested by HPLC-MS/MS analysis. RESULTS: C14:0 and C24:1 levels were significantly higher in PDD than in PD-NC and normal controls. Verbal memory was negatively correlated with C14:0 and C24:1. After controlling for confounding factors, C22:0, C20:0 and C18:0 were significantly associated with hallucinations, anxiety and sleep behavior disturbances, respectively. CONCLUSION: In PDD, the increase in ceramide levels was correlated with decreased memory function and associated with higher odds of multiple neuropsychiatric symptoms.
Authors: Julie-Myrtille Bourgognon; Jereme G Spiers; Hannah Scheiblich; Alexey Antonov; Sophie J Bradley; Andrew B Tobin; Joern R Steinert Journal: Cell Death Differ Date: 2018-06-18 Impact factor: 15.828
Authors: Judith Wackerlig; Harald C Köfeler; Volker Korz; Ahmed M Hussein; Daniel D Feyissa; Harald Höger; Ernst Urban; Thierry Langer; Gert Lubec; Jana Lubec Journal: Front Aging Neurosci Date: 2020-07-03 Impact factor: 5.750
Authors: Kamilah Castro; Achilles Ntranos; Mario Amatruda; Maria Petracca; Peter Kosa; Emily Y Chen; Johannes Morstein; Dirk Trauner; Corey T Watson; Michael A Kiebish; Bibiana Bielekova; Matilde Inglese; Ilana Katz Sand; Patrizia Casaccia Journal: EBioMedicine Date: 2019-04-10 Impact factor: 8.143